Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Biomarkers experts stories

Sep 25, 2026

Blood-based biomarkers reshape Alzheimer's disease diagnostic approach

Medical experts are sequencing plasma p-tau217 and beta-amyloid 42/40 testing alongside cognitive screening as first-line diagnostic tools for Alzheimer's disease, reserving confirmatory amyloid PET or CSF testing for inconclusive cases. Payer coverage for these biomarker tests has expanded, marking a shift in the diagnostic toolkit.

Sep 25, 2026·3 sources
00
Jul 15, 2026

Blood Test Using P-Tau217 Biomarker Can Predict Alzheimer's Risk Years Before Symptoms Appear, Study Finds

A new study demonstrates that a blood test measuring p-tau217 levels can identify healthy older adults at high risk of developing Alzheimer's symptoms within five to 10 years, potentially enabling early intervention as prevention trials advance.

Jul 15, 2026·5 sources
00
Apr 14, 2026

Blood Test Predicts Alzheimer's Progression Years Before Symptoms or Brain Scan Changes

Mass General Brigham researchers found that plasma phosphorylated tau 217 (pTau217) blood test can predict progression of amyloid PET scans years before symptoms appear or brain imaging shows changes.

Apr 14, 2026·1 source
00
Apr 6, 2026

UCLA Researchers Develop Blood Test to Detect Multiple Cancers and Diseases Simultaneously

Scientists at UCLA have developed a simple and cost-effective blood test that shows promise in early studies for detecting multiple cancers, various liver conditions, and organ abnormalities from a single blood sample.

Apr 6, 2026·1 source
00

Top claims

  • ▪Research indicates that ionizing radiation triggers DNA damage and brain immune cell responses that release the protein eCIRP, which appears to cause phosphorylation in tau proteins.
  • ▪A review published in Frontiers in Immunology by researchers from Hofstra University and Northwell Health suggests that exposure to ionizing radiation may trigger biological changes in the brain resembling Alzheimer's disease.
  • ▪Reproducibility in biomarker development is challenged by cohort-specific effects, pre-analytical variability, platform drift, batch effects, and confounding factors from concomitant diseases and treatments.

Subtopics

Alzheimer’s & dementia2Brain health & dementia researchers2Brain longevity2Drug Approval and Clinical Trials2Drug Policy, Pricing & Approval2Age related cognitive decline1Biomarkers & bloodwork testing1Longevity & biohacking1Preventive longevity physicians1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories